

Hereditary Spherocytosis and Venous Thrombosis of Atypical Site: A Triple Hematologic Disease?

Santiago Andrés Guzmán – García^{*1}, Gonzalo Anwar Montalvo¹, Anwar García-Santos¹, Ana Karen Valenzuela-Vidalez¹, Emilio Conde-Flores¹, Aldo Lara-Reyes¹, Leslie Rocha¹, Brenda Reynoso², Luis Guevara-Arnal³ and Sergio Arturo Sánchez-Guerrero⁴

¹Department of Internal Medicine Unit, Resident, Medica Sur Clinic and Foundation, Mexico City, Mexico ²Department of Pathology Medicine, Medica Sur Clinic and Foundation, Mexico City, Mexico ³Department of Hematology, Treating Physician, Medica Sur Clinic and Foundation, Mexico City, Mexico ⁴Department of Nephrology, Treating Physician, Medica Sur Clinic and Foundation, Mexico City, Mexico

***Corresponding author:** Santiago Andrés Guzmán – García, MD., Department of Internal Medicine Unit, Resident, Medica Sur Clinic and Foundation, Puente de Piedra #150, Col. Toriello Guerra ZP, Tlalpan, Mexico City, Mexico 14050, Tel: (+52) 554247200 Ext: 4119, E-mail: saggrecho@hotmail.com

Citation: Santiago Andrés Guzmán – García, Gonzalo Anwar Montalvo, Anwar García-Santos, Ana Karen Valenzuela-Vidalez, Emilio Conde-Flores, et al. (2016) Hereditary Spherocytosis and Venous Thrombosis of Atypical Site: A Triple Hematologic Disease? J Hematol Blood Disord 2(2): 201. doi: 10.15744/2455-7641.2.201

Received Date: April 12, 2016 Accepted Date: June 02, 2016 Published Date: June 04, 2016

Background

A 22 year-old male with an unspecified family history of hematologic diseases was admitted complaining of chest pain. A diagnosis of thrombosis of supra-aortic vessels and hereditary spherocytosis was established and, because there is not a causal relationship between these two disorders, an approach intended to rule out primary or secondary thrombophilia is herein mentioned.

Keywords: Hereditary spherocytosis; Primary thrombophilia; Thrombosis of atypical site; Antiphospholipid antibody syndrome

List of Abbreviations: HS: Hereditary Spherocytosis; AFA: Antiphospholipid antibodies

Introduction

Hereditary spherocytosis is part of a group of disorders of the erythrocyte membrane such as hereditary stomatocytosis, eliptocytosis and ovalocytosis which mainly manifest as a regenerative hemolytic anemia. Its etiology comes from genetic alterations of membrane and structural proteins which disturb the erythrocyte cohesion and stability. HS also known as Minkowski Chauffard's Disease, has a prevalence of 1 in 2000-3000 patients in north America and north Europe however a great number of cases remain asymptomatic [1]. This heterogeneous disease is characterized by spherical-shaped erythrocytes seen in the peripheral blood smear [2], which have a reduced physiological strain capacity due to anomalies of well identified membrane proteins such as ankirin, alpha y beta espectrin, band 3 and protein 4.2, this leads to a wide spectrum of clinical presentations varying in severity and age of onset [3]. In general, alpha spectrin anomalies have an autosomic recessive inheritance while beta spectrin has an autosomic dominant pattern which influences the severity of disease. The more common altered protein is ankirin representing 40-65% of all cases [4]. HS can manifest at any age but typically in adolescents and young adults; severe cases manifest at birth. Clinical manifestations include but are not limited to hemolytic anemia, splenomegaly, jaundice, bilirubin gallstones, increased osmotic fragility 50 and family history of disease [5]. Diagnosis is based in the last two in addition to mean corpuscular hemoglobin concentration (MCHC) >36 g/dl and flow cytometry with dye eosin 5 -maleimidin (EMA) which show the loss of normal erythrocyte Surface, Cryohemolisis or osmotic fragility test [2]. Treatment is determined by the severity of disease and risk-benefit of splenectomy [6]. Below we describe a clinical case of a 22 year-old male patient with HS and a venous thrombosis in an atypical site, in which, after a diagnostic approach we suspect of a triple hematologic condition: hereditary spherocytosis, primary thrombophilia and antiphospholipid antibody syndrome.

There are no reported cases of spontaneous deep venous thrombosis in patients diagnosed with HS.

The S and C proteins are vitamin K-dependent glycopoeins that serve as part of the regulston system of the coagulation cascade. Its deficiency leads to increased generation of thrombin secondary to the absence of inactivation of activated V and VIII factors. Acquired deficiency of this proteins, can be functionally divided in 2: Increased consumption or decrease in their synthesis; the

first is due to pharmacological inhibition by vitamin K antagonists or due to a severe depletion of vitamin K, as well as chronic liver disease which can be demonstrated in patients with end-stage cirrhosis. None of these conditions occurred in this patient; however acquired etiologies are more frequent than congenital, with an estimated prevalence of 0.3% and 0.1% for protein C and S deficiency respectively [7].

Clinical Case

A 22 year-old male patient presents to the clinic with a 5-day history of progressive thoracic oppressive pain, radiated to the left jaw. His personal medical record is irrelevant except by history of neonatal jaundice. He has family history of hematologic conditions; his great grandmother and grandmother were splenectomized of unknown cause, and his mother has recurrent anemia. Physical examination reveals generalized jaundice and massive splenomegaly; the inferior border of the Spleen is palpated three cm above the left anterior superior iliac spine, surpassing the abdomen midline. A Doppler ultrasound was performed revealing an intraluminal filling defect of the internal jugular vein, compatible with thrombus. Extended evaluation with a CT angiography showed thrombosis of the left internal jugular, innominate and subclavian veins, splenomegaly of 24 cm on its sagittal axis and no images compatible with pulmonary thromboembolism (Figure 1, 2a, 2b, 3 and 4). Laboratory tests show normocytic normochromic anemia with a wide red cell distribution width (RDW), prolonged activated partial thromboplastin time (aPTT), indirect hyperbilirubinemia and high levels of lactate dehydrogenase (Table 1). Peripheral blood smear showed few spherocytes, ghost cells, macrocytosis and moderate microcytosis and ovalocytosis (Figure 4 and 5). Anticoagulation with enoxaparin (1mg/kg) was started. Because of this findings and the suspicion of HS, diagnostic approach was complemented with an acute viral hepatitis panel and ELISA for HIV with non-reactive results, positive osmotic fragility test compatible with the diagnosis of HS and a mix study with non-correction of aPTT (Table 1).



Figure 1: Contrast-enhanced CT (venous phase) Axial view: Filling defect is observed at the junction of the middle and lower third of internal left jugular vein with 95% occlusion of venous outflow



Figure 2a: Sagittal section prior administration of contrast: Filling defect is observed at the level of left internal jugular vein



Figure 2b and 3: Abdominal CT angiography, coronal and axial view: massive splenomegaly measuring 23.25 x 15.29 x 9.92cm associated with retroperitoneal peripancreatic lymphadenopathy



Figure 4 and 5: Peripheral blood smear: Erythrocytes lacking of pale center (typical characteristics of spherocytes). Hypochromic microcytic cells with central halo, some with minimum amount of hemoglobin (ghost cells). Macrocytes without polychromasia. Oval-shaped cells with no paralleled halos. Normochromic cytoplasm and hypochromic in others without polychromasia

Complete Blood count			Coagulation tests			
Parameter	Result	Reference range	Parameter	Result	Reference range	
Hemoglobin	12.3 g/dl	14-18 g/dl	TP 12 secs.		9-12 secs	
Hematocrit	34.4 %	42-54%	ТТР	48.1 secs. (control 26.7)	24.4-31.8 secs.	
MCV	84.5 fL	80-96fL	Correction		-	
МСН	30.1pg	27-33 pg	Dilution 1:2 (patient/control)	37 secs	-	
МСНМ	25.5%	11.5-15.5 %	Dilution 1:4 (patient/control)	30.5 secs	-	
RDW	25.5%	11.5-15.5 %	Dilution 1:8 (patient/control)	27.4 secs	-	
Platelets	168 x10 ^3/μL	150-450 x10 ^3/μL	INR	1.09	-	
Leucocytes	9.4 x10 ^3/μL	4.5-11 x10 ^3/μL	Dimer D	390 ng/ml	0-199 ng/ml	
Neutrophils	5.6 x10 ^3/μL	1.8-7 x10 ^3/μL				
Lymphocytes	3.1 x10 ^3/μL	1.2-4 x10 ^3/μL				
Reticulocytes	16%	<2%				
Haptoglobin	<5 mg/dl	-				
	Liver Function Tests		Serum Electrolytes			
Parameter	Result	Reference range	Parameter	Result	Reference range	
Total proteins	7.3 g/dl	6.1-7.9mg/dl	Sodium	139 mmol/L	136-144 mmol/L	
Albumin	5.01 g/dl	3.5-4.8 mg/dl	Potassium	3.79 mmol/L	3.6-5.1 mmol/L	
Globulins	2.3 g/dl	2.3-3.8 mg/dl	Chlorine	105.2 mmol/L	101-111 mmol/L	
Total Bilirubin	4.98	0.4-1.5 mg/dl	CO ₂	27 mmol/L	22-32 mmol/L	
Direct Bilirubin	0.25	0-0.3 mg/dl	Corrected Calcium	8.8 mg/dl	8.9-10.3 mmol/L	
Indirect Bilirubin	4.73	0.3-1.4 mg/dl	Phosphorus	4.7 mg/dl	2.4-4.7mg/dl	
ALT	22 U/L	17-63 U/L	Magnesium	1.89 mg/dl	1.8-2.5mg/dl	
AST	26 U/L	15-41 U/L				
AF	75 U/L	32-91 U/L				
GGT	12 U/L	7-50 U/L				
LDH	368 U/L	49-397 U/L				
Blood Chemistry			Urinalysis			
Parameter	Result	Result	Parameter	Result		
Glucose	95mg/dl	95mg/dl	Bilirrubin	1+		
BUN	11.3 mg/dl	11.3 mg/dl	Proteins	traces		
Urea	24.2 mg/dl	24.2 mg/dl				

	Blood Chemistry		Urinalysis			
Parameter	Result	Result	Parameter Result			
Creatinine	0.76 mg/dl	0.44-1.03 mg/dl				
	APS panel		Coagulation Panel			
Parameter	Result	Reference range	Parameter	Result	Reference range	
Lupic Anticoagulant	Detected	-	Direct Coombs	Positive	Negative	
Ac IgA anticardiolipin	<9	-	Protein S activity	48%	70-150%	
Ac IgG anticardiolipin	>560	>80 positive	Protein S antigen	80%	60-150%	
Ac IgM anticardiolipin	<2	0-12.9	Total Protein S	80%	58-150%	
Anti beta 2 glycoprotein	1.2	-	Free Protein S	61%	56-124%	
			Protein C activity	57%	70-180%	
			Protein C antigen	62%	70-140%	
			Mutation 20210	Normal	Normal	
			Leiden mutation	Normal	Normal	
	Viral Panel					
Parameter	Result	Reference range	Parameter	Result	Reference range	
HBV HCV	Non-reactive	Non-reactive	Hip osmotic solution			
HIV 1 y 2	Non-reactive	Non-reactive	0.85% (initial hemolysis)	Positive	0.45-0.5%	
VDRL	Positive 1:8	Negative	0.55% (complete hemolysis)	Positive	0.3-0.4%	

Table 1: Laboratory Tests

An isolated prolonged aPTT result with a normal prothrombin time result implies either the presence of heparin, an inhibitor (either specific factor or lupus anticoagulant), or a factor deficiency of the intrinsic system. A mixing study may be necessary to determine the etiology. To perform it, the patient specimen is mixed with an equal volume of normal platelet free plasma, and another volume mixed with an equal volume of veronal buffered saline. APTTs are performed on each of these mixtures. An aliquot of the normal plasma/patient plasma mixture is also incubated at 37 °C for one to two hours and then an aPTT performed to further clarify the cause of the prolongation As a control, normal platelet free plasma and patient plasma are also incubated separately and then mixed after this incubation as a control for possible factor degradation during incubation.

If the result obtained with the immediate normal plasma mixture corrects to within the reference range and the saline mixture result increases dramatically, a factor deficiency or specific factor inhibitor is suspected. With factor deficiency, heparin or a specific factor inhibitor, the 1:1 saline mix shows significant prolongation of the aPTT result. If the result obtained with the immediate normal plasma mixture shows only partial or no correction and the result obtained with the saline mixture shows near correction to the reference range or only mild prolongation, then a nonspecific inhibitor such as lupus anticoagulant (LA) is suspected. After incubation at 37 °C, an aPTT result equivalent to that of the original mixture is indicative of a factor deficiency or heparin. If the result of the APTT on the incubated mixture demonstrates further prolongation (with the control remaining equivalent to the original mixture, but will demonstrate prolongation upon incubation. Factor deficiencies should be further identified by performing specific factor assays. Plasma suspected of containing a lupus anticoagulant (LA) should be further tested with other LA specific tests [i.e., Dilute Russell Viper Venom Time (DRVVT), Platelet Neutralization Procedure (PNP), or the Hexagonal Phospholipid Neutralization Procedure] to confirm the presence of a lupus anticoagulant.

Russell's viper venom activates the coagulation system by directly activating FX. In the DRVVT, the term dilute refers to the reduced concentration of phospholipid used in the reagent, to increase sensitivity for Lupus Anticoagulants (LA). Lupus anticoagulants typically cause prolongation of the dilute Russell's viper venom time. The DRVVT may be advantageous over the aPTT as a screen for LA in some instances, as this reaction does not involve FVIII. FVIII can elevate as an acute phase reactant and shorten the aPTT, diminishing the degree of prolongation seen with some lupus anticoagulants. DRVVT Confirm is a DRVVT assay which utilizes an increased phospholipid concentration. The DRVVT assay is performed in the presence of dilute phospholipid and concentration increased to show phospholipid dependence. A ratio of screen/confirm is reported [4].

Journal of Hematology and Blood Disorders

Being a young patient with no known risk factors for venous thrombosis and with a mix study with non-correction of aPTT, a workout for evaluating the presence of a primary thrombophilia was started. Antiphospholipid antibody syndrome panel showed the presence of lupic anticoagulant and IgG anticardiolipin antibodies; low activity of proteins C and S and negative G20210A prothrombin gene and Leiden V factor mutation.

During his hospitalization, he had adequate response to anticoagulation treatment with good clinical improvement, so bridging anticoagulation was performed with warfarin and was discharged. He received anticoagulant treatment during 3 months with resolution of thrombosis and was evaluated ambulatory 6 weeks later with coagulation tests to confirm the persistence of the anomalies previously documented.

Clinical Case

How the diagnosis of HS is made?

- a. Spherocytes in peripheral blood smear
- b. Jaundice and anemia
- c. Laboratory test: osmotic fragility test, cryohemolysis or EMA test
- e. All of the above
- Correct answer: E

HS clinical presentation is heterogeneous: Clinically (asymptomatic, mild, moderate and severe disease) biochemically and genetically. Infections (Parvovirus B19, Citomegalovirus o Gastroenteritis) and other clinical states such as pregnancy can exacerbate the condition of asymptomatic patients or those with a mild disease form [1].

During the diagnostic approach, is important to inquire about family history, look and ask for the presence of typical manifestations such as jaundice, anemia and splenomegaly. Look pointedly for characteristic laboratory test results like normocytic normochromic anemia, reduced MCV, high MCHC in addition, spherocytes and reticulocytes in the PBS. With the previous data we can integrate the diagnosis, without performing other tests [2]. Nevertheless, when an accurate diagnosis can't be made we can perform confirmatory test such as glycerol lysis test, acidified glycerol lysis time and pink test; which determine the extension or percentage of lytic erythrocytes suspended in glycerol. Osmotic fragility test which determines the concentration of sodium chloride at which erythrocytes break at 50% and EMA flow cytometry test which binds to membrane proteins and determines the amount of fluorescence of erythrocytes with flow citometry. If the diagnosis is equivocal, a screening test with high predictive value for HS is helpful. The recommended screening tests are the cryohemolysis test and EMA binding (Table 2).

Diagnosis recommendations in HS [2]				
1. Newly diagnosed patients with a family history of HS, typical clinical features (splenomegaly) and laboratory investigations (spherocytes, raised MCHC, increase in reticulocytes) do not require any additional tests (1A).				
2. If the diagnosis is equivocal, e.g. where there are a few spherocytes on the film but no other laboratory, clinical or family evidence, a screening test with high predictive value for HS is helpful. The recommended screening tests are the cryohemolysis test and EMA binding (1A).				
3. Confirmation of diagnosis may be necessary in selected cases if the screening tests produce an equivocal or borderline result. Gel electrophoresis analysis of erythrocyte membranes is the method of choice.				
4. Diagnosis of HS does not require further investigation by molecular analysis of the affected genes				
Thrombophilias most common primary prevalence and relative risk in clinical manifestations [28] Table 2: Diagnosis recommendations in HS [2]				

Our patient presented with jaundice, splenomegaly, family history of hematologic conditions and laboratory tests with microcytic hypochromic anemia with spherocytes in the PBS, which oriented the diagnostic approach. After this, an osmotic fragility test was performed, resulting in initial hemolysis with 0.85% hypotonic solution and complete hemolysis with 0.55% solution, confirming the diagnosis of HS. Other test can be used to confirm the diagnosis, like glycerol acidification lysis test or the pink test, though their sensitivity varies being 68% in the glycerol acidification lysis test, 61% in the osmotic fragility test, and 91% in the Pink test. As an alternative, we can ask for an EMA flow cytometry test being positive in >21% of cases with a sensitivity of 92.7% and specificity of 99.1% [3].

With the previous data, our patient can be catalogued with a moderate disease because he had an hemoglobin >8.0 g/dL, 16% reticulocytes, high osmotic fragility and no need of transfusions.

What is the treatment for HS?

a. Medical management with annual monitoring and folate supplementation.
b. Surgery
c. Steroids
d. A y B
Right answer: D (Medical management and Surgery)

Clinical management of hereditary spherocytosis is individualized according to severity; considering folate supplementation (5mg day) in mild and moderate cases and surgical management with splenectomy in severe cases with the purpose of reduce hemolysis, its complications and transfusion requirements [4]. When splenectomy is considered, vaccination against encapsulated microorganisms is mandatory. Cholecystectomy can be performed in cases of coexisting gallstone disease in patients of above 10 years-old [5].

British guidelines recommend that splenectomy technique depends on the surgeon training, although a laparoscopic approach is associated with less post-surgical pain, intrahospital stay and better aesthetic results. Partial splenectomy confers minimum postsurgical sepsis risk but is associated with recurrence of hematological complications. Several studies evidence that total splenectomy does not increase the postsurgical sepsis mortality [2].

A patient with HS should be monitored annually with CBC, liver and gallbladder ultrasound or iron profile test depending on the severity of disease [3]. For the mentioned above, our patient should be monitored annually with laboratory tests according to severity and folate supplementation. In severe cases, where symptomatic thrombocytopenia or splenic infarction, splenectomy can be considered.

How the antiphospholipid antibody syndrome is diagnosed?

a. Recurrent venous or arterial thrombosis associated to an autoimmune disease

b. Presence of moderate or high levels of antiphospholipid antibodies in two or more occasions separated by at least 12 weeks and two clinical criteria

c. At least one clinical criteria and at least one laboratory criteria with moderate or high levels in more than two occasions, separated by at least 6 weeks

d. At least one clinical criteria and at least one laboratory criteria with moderate or high levels in one occasion Correct answer: B

Antiphospholipid syndrome is characterized by the presence of venous or arterial thrombosis, pregnancy specific diseases and the presence of antiphospholipid antibodies [6].

Antiphospholipid antibodies are directed against phospholipids-binding plasma proteins, and its presence can be demonstrated by ELISA. IgG and IgM anticardiolipin antibodies present at moderate or high blood levels in two or more occasions, separated by at least 12 weeks and lupus anticoagulant detected in blood in two or more occasions separated by at least 12 weeks, according to the guidelines of the International Society on Thrombosis and Hemostasis [7]. The definitive diagnosis of antiphospholipid syndrome requires the presence of at least one of the clinical criteria and at least one of the laboratory criteria. There are no limits intervals between clinical events and the positive findings in the laboratory. Antiphospholipid antibodies that are not included in the diagnostic criteria are: anticardiolipin IgA antibodies, anti B2-glycoprotein I antibodies and antiphospholipid antibodies directed against other phospholipids.

In the case of our patient, he presented with subclavian, left brachiocephalic and ipsilateral internal yugular thrombosis, in addition, prolonged aPTT was found in the laboratory tests. Lupus anticoagulant and anticardiolipin antibodies in a titer IgG> 560, confirmed the diagnosis.

What is the treatment of Antiphospholipid antibody syndrome?

- a. Anticoagulation with anti-vit K for 6 months (INR 2-3)
- b. Low doses of ASA with hydroxychloroquine until low levels of antiphospholipid antibodies are documented
- c. Anticoagulation with anti-vit K (INR 2-3) for 5 years
- d. Anticoagulation with anti-vit K (INR 2-3) for undefined time

Before starting the treatment, its necessary to consider that carriers of antiphospholipid antibodies (AFA) do not have an homogeneous risk of thrombosis; several parameters must be taken into account to accurately stratify the risk of developing a vascular event.

1. AFA profile: Each AFA profile gives a characteristic thrombotic risk. Among the AFA, lupus anticoagulants (LA) have the strongest predictive value for clinical vascular events, increasing the risk of thrombosis by four [8,9]. Thrombotic risk increases with the number of positive tests for LA. According to the classification criteria, patients with antiphospholipid antibody syndrome can be stratified into four categories depending on the number of positive tests: Class I includes patients with more than one positive result in any combination, while patients with a single positive test should be classified in category II.

2. Associated autoimmune disorders: Patients with underlying systemic autoimmune disease have an increased vascular mobility. In particular, positive AFA, have been identified as one of the main determinants of thrombosis among patients with systemic lupus erythematosus [10,11].

Correct answer: D

Journal of Hematology and Blood Disorders

3. Cardiovascular risk factors: Hypertension has become an independent predictor for presenting a first thrombotic episode in AFA carriers. That's why a careful evaluation of cardiovascular status is recommended: Age, diabetes, hypertension, dyslipidemia, obesity, smoking, sedentary lifestyle, hyperhomocysteinemia, protein C and protein S, ATIII deficiency, Factor V Leiden mutation, prothrombin time, immobilization, prolonged surgery or procedures and the use of estrogen replacement therapy [12].

4. Site of thrombosis: Patients, whose first thrombosis event is arterial, are considered at higher risk of recurrence, in the same arterial distribution [13]. Treatment of AFAS remains controversial; any therapeutic decision could result in excessive or insufficient anticoagulation. The indication of indefinite anticoagulation is consensual, but its intensity and possible interruption are discussed. The new anticoagulant agents (Rivaroxaban and dabigatran), are still being studied in patients with AFAS and its use is not yet recommended. Pharmacological agents used in the treatment of thrombotic AFAS counteract the effects of AFAS preventing coagulation, including antiplatelet agents such as aspirin at low doses. Anticoagulant drugs include vitamin K antagonists (VKA), heparin and its derivatives. Treatment with AVK presents several difficulties. These agents have a slow onset of action, narrow therapeutic range and require frequent monitoring with INR. They interact with a great number of foods and drugs including immunosuppressive agents. AFA detection is affected with the use of VKA, limiting AFAS diagnosis [13]. The efficacy of heparin in the AFAS treatment is not only attributable to its anticoagulant action. Heparin interacts directly with β2GPI, diminishing its prothrombotic activity [14]. Bleeding risk: The risk of bleeding in patients with INR of 2.0-3.0 is 0.8-1.6%. The mortality due to thrombosis is higher than the death rate due to bleeding [15]. Patients with positive AFA without SLE are considered at high risk of thrombosis, so they should use low-dose aspirin. Patients with SLE and positive AFA should use hydroxychloroquine and lowdose aspirin. Patients without SLE who have experienced a primary non-cardioembolic stroke with a low risk AAF profile and modifiable risk factors should be considered for antiplatelet therapy. Patients with definite AFAS, who have presented thrombosis, should maintain antithrombotic medication indefinitely. Patients with primary venous thrombosis with a low risk profile, plus a known risk factor may have a limited duration of anticoagulation treatment for 3-6 months. Events of venous thrombosis. The initial therapy consists of unfractionated heparin or low molecular weight along with anticoagulant agents with at least 5 days (bridge therapy), seeking an INR 2.0-3.0, for an indefinite period, The persistence of anticardiolipin antibodies after 6 months of a venous thrombosis; predict thrombotic recurrence and death [13] Arterial thrombotic events: The patients with history of arterial thrombosis and AFA should use warfarin for an indefinite time (INR 2-3 or INR >3) with or without antiplatelet agents. Although prospective studies have not found any difference between INR 2-3 or INR >3, making difficult to take any definitive conclusion. We suggest long term anticoagulant therapy with warfarin intensive therapy. Additional therapeutic options: Hydroxychloroquine, which has been proved to have immunomodulatory effects; preventing the activation of TLR3, TLR7 and TLR9. Avoids the processing and presentations of antigens and plasma reduce immune complexes. It has shown to inhibit the expression of 2b-3a glycoprotein inactivating platelets, reverses the complex formation in the cellular membrane of β 2GPI antibodies and Phospholipids. There's few clinical evidence of its antithrombotic effects in AFAS. The treatment guidelines consider hydroxychloroquine as a potential adjuvant therapy, particularly to its excellent safety profile. New anticoagulant agents: The role of the new anticoagulant agents in AFAS is yet not determined. There are few clinical randomized clinical assays that evaluate its role in the AFAS treatment. Statins: The use of statins could be beneficial in preventing thrombosis, because hypertriglyceridemia and low levels of HDL-Cholesterol are the most frequent cardiovascular risk factor in patients with AFAS. Nevertheless they have also proved to have an antithrombotic and anti-inflammatory effect. Vitamin D has an antithrombotic and immunomodulatory effect through the inhibition of β 2GPI antibodies.

In our patient, anticoagulation bridging therapy was started with enoxaparin 60mg SC BID for 5 days and acenocumarol. If AFAS diagnosis is confirmed, the anticoagulation will continue indefinitely with an INR 2-3.

What is the most common primary thrombophilia?

- a. Antithrombyn deficiency
- b. Protein C or S deficiency
- c. Factor V Leiden
- d. Double pro coagulant lesion: Prothrombin/Leyden's V Factor gene mutation
- Correct answer: C

The overall prevalence of this primary thrombophilia was described by the Dutch University of Leiden in 1994 as the most common worldwide. It is characterized by a resistance of the Factor V for its inactivation by the protein C and has a current prevalence of approximately 4%, followed by mutation of the prothrombin gene and subsequently high risk thrombophilias, which are characterized by deficient endogenous anticoagulants. Reports in the Mexican population suggest a similar prevalence. Remember that the diagnoses of the 2 most common thrombophilias are based on genetic tests, which yield a high diagnostic certainty [14-16].

When should we suspect of a primary thrombophilia?

- a. First-degree relative with unprovoked venous thrombosis
- b. Thrombosis of unusual site
- c. Multiple Thrombosis

d. All of the above Correct answer: D.

The evidence of thrombosis in patients diagnosed with primary thrombophilia is scarce, however the most important association in the diagnosis of primary thrombophilia is a history of unprovoked thrombosis in a first-degree relative (mother, father or sibling) or familial tendency of venous thrombosis defined as 2 or more relatives with unprovoked venous thrombosis. The diagnosis of multiple thrombosis has a higher association with the phenomenon of cardio embolism (i.e. Atrial Fibrillation) [17,18]. A tendency of retinal vein thrombosis and the presence mutation of prothrombin gene especially in patients receiving hormonal replacement therapy is seen in primary thrombophilia. Venous thrombosis of unusual site refers to venous thrombosis in retinal, cerebral and intra-abdominal veins. In the case of this patient we have an event of unprovoked thromboembolism in unusual site in a young patient with no risk factors [17,19-21].

What are the reasons why it is justified not make immediate diagnosis of primary thrombophilia?

a) In the acute event, the coagulation cascade and all pro and anticoagulant events are modified due to thrombosis itself and the effect of anticoagulation therapy

b) Women of reproductive age because of high risk of complications in this group and patients with hematologic double injury pro coagulant (extremely rare prevalence) that could benefit from prolonged or indefinite anticoagulation c) A y B

d) Patient with a mutation in the prothrombin gene, protein S or C deficiency (considered S high-risk thrombophilia) do not change the choice or duration of treatment

Correct answer: B

Identification and diagnosis of a patient with primary thrombophilia has no utility in the acute event of thrombosis for 2 main reasons: in the acute event, the coagulation cascade and all pro and anticoagulant events are modified due to thrombosis itself and the effect of anticoagulation therapy. The second reason is that identifying a patient with a mutation in the prothrombin gene, protein S or C deficiency (considered s high-risk thrombophilia) does not change the choice or duration of treatment. Two scenarios could probably glimpse benefit: women of reproductive age because of high risk of complications in this group and patients with hematologic double injury pro coagulant (extremely rare prevalence) that could benefit from prolonged or indefinite anticoagulation. Younger patients (<40 years) without comorbidities, have higher probability of a positive pro coagulant profile as in the case of our patient. As mentioned before, the two most common primary thrombophilia's are diagnosed with genetic tests, whose results are not affected by the acute event of thrombosis and although there is no conclusive evidence of the usefulness of measuring levels of antithrombin, protein S or C in the acute event, theoretically the presence of normal values has a high negative predictive value for primary thrombophilia [20].

During follow-up, further studies should be made?

a. Yes, Dimer D

b. Yes, serum Thrombin

c. No impact on decision-making regarding treatment

d. Repeat the thrombophilia profile to avoid false positives

Correct answer: C

Thrombophilia profile includes: Antithrombin: functional assay (Anti-Xa cofactor activity). Protein C: functional assay (Chromogenic with snake venom). Protein S: unspecific functional assay, total or free antigen can be measured. Activated Protein C Resistance: based on aPTT with or without Factor V poor plasma. The result must be confirmed with Genotype for Factor V Leiden G20210A mutation. Antiphospholipid antibodies: phospholipid dependent tests for lupus anticoagulant (with Kaolin Clotting Time (KCT) and Russell viper venom diluted time (dRVVT) and anticardiolpin antibodies [22] (Table 3).

Diagnostic tests are of less value than the clinical characteristics of the patient as a predictor of recurrence. Laboratory studies should be limited to the subgroup of patients where results impact treatment (antiphospholipid syndrome, pregnancy, family history or hereditary disease history). Only in some cases the studies must be repeated in optimal conditions to avoid false positives [1]. There are some studies that have attempted to demonstrate the need to restart the anticoagulant therapy in patients who had a previous episode of spontaneous thromboembolism and received treatment for at least 6 months. D-dimer, serum levels of Thrombin and genetic studies are some of them although the cost-benefit evidence is not clear [23].

In this case venous thrombosis occurs in the context of a prolonged aPTT, confirmed 12 weeks after the acute episode with low levels (but not deficiency) of protein C and S in addition to a diagnosis of a hereditary symptomatic erythrocyte membrane disorder. We can conclude that regularly repeated studies on pro coagulant hereditary disease (thrombophilia) is not cost-effective and does not impact the treatment which is based on risk stratification according to clinical characteristics. However it is important to always individualize the case, especially in patients presenting with various bleeding disorders since in these cases it is clear that there is a greater risk of recurrence.

	Antithrombin deficiency	Protein C deficiency	Protein S deficiency	Factor V Leiden	Prothrombin 20210A mutation	Lupus antico- agulant*	Anti- cardiolipin antibodies	Anti-B2 GPI antibodies
Prevalence in the general population	0.02%	0.2%	0.03%-0.13%	3-7%	0.7-4%	1-8%	5%	3.4%
Relative risk for a first venous thrombosis	5-10	4-6.5	1-10	3-5	2-3	3-10	0.7	2.4
Relative risk for recurrent thrombosis	1.9-2.6	1.4-1.8	1.0-1.4	1.4	1.4	2-6	1-6	No data
Relative risk for arterial thrombosis	No association	No consistent association	No consistent association	1.3	0.9	10	1.5-10	No data

Table 3: Prevalence of thrombophilia and relative risk estimates for various clinical manifestations [28]

For how long should anticoagulant therapy be given?

a. 3 to 6 months

- b. 1 year
- c. Undefined
- d. Individualized
- Correct answer: D

Taking into account the determinants of the recurrence of a first episode of venous thrombosis help in making treatment decisions. Age (> 65 years), history of a previous episode, antiphospholipid syndrome diagnosis, male and proximal thrombosis are some of them [22]. There are risk stratification models that identify patients at high risk of recurrence where the indefinite anticoagulant therapy is mandatory in contrast to patients with lower risk [24].

The optimal long term management strategy in patients with an episode of venous thromboembolism (VTE) is controversial. The evidence is irrefutable in patients with VTE and cancer as well as in patients with a second episode of unprovoked VTE where treatment duration is undefined [25]. We must take into account the risk of bleeding versus the risk of recurrence. The evidence show that during the first 6 months to 1 year the risk of thromboembolism and major bleeding is the same, however after the first year the risk of VTE recurrence significantly decreases and the risk of major bleeding keeps the same. According to the Current Antithrombotic Therapy and Prevention of Thrombosis Guidelines, a patient with a low or moderate bleeding risk, extended anticoagulant therapy is recommended. The continuing use of treatment should be reassessed annually [26].

In our patient the treatment was indicated for at least 6-12 months. Sex, location and diagnosis of Antiphospholipid Antibody Syndrome are factors to consider in the decision to extend the treatment however we must stratify and take into account the risk of long-term bleeding [27].

References

1. King MJ, Zanella A (2013) Hereditary red cell membrane disorders and laboratory diagnostic testing. Int J Lab Hematol 35: 237-43.

2. Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ, et al. (2012) Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Br J Haematol 156: 37-49.

3. Da Costa L, Galimand J, Fenneteau O, Mohandas N (2013) Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev 27: 167-78.

4. Kamal AH, Tefferi A, Pruthi RK (2007) How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults. Mayo Clin Proc 82: 864-73.

5. Rice HE, Englum BR, Rothman J, Leonard S, Reiter A, et al. (2015) Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. Am J Hematol 90: 187-92.

6. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295-306.

7. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA (2010) Antiphospholipid syndrome. Lancet 376: 1498-509.

8. Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, et al. (2013) Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res 65: 1869-73.

9. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, et al. (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 3: 1993-7.

10. Meroni PL, Chighizola CB, Rovelli F, Gerosa M (2014) Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers. Arthritis Res Ther 16: 209. 11. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61: 29-36.

12. Ruffatti A, Del Ross T, Ciprian M, Nuzzo M, Rampudda M et al. (2009) Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 68: 397-9.

13. Meroni PL, Borghi MO, Raschi E, Tedesco F (2011) Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 7: 330-9.

14. Chighizola CB, Ubiali T, Meroni PL (2015) Treatment of Thrombotic antiphospholipid Syndrome: The Rationale of Current Management—An Insight into Future Approaches. J Immunol Res DOI: 10.1155/2015/951424.

15. Yang P, Kruh JN, Foster CS (2012) Antiphospholipid antibody syndrome. Curr Opinion Ophthalmol 23: 528-32.

16. Martínez-Murillo C, Romo-Jiménez A, Zavala-Hernández C, Gaminio-Gómez E, Montaño-Figueroa EH, et al. (2010) Trombofilia primaria en México: experiencia de una institución. Rev Med Hosp Gen Mex 73: 225-30.

17. MacCallum P, Bowles L, Keeling D (2014) Diagnosis and management of heritable thrombophilias. BMJ 349: 10.1136/bmj.g4387.

18. Guyatt GH, Akl EA, Crowther M, Schünemann HJ, Gutterman DD, et al. (2012) Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: 48S-52S.

19. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, et al. (2010) Clinical guideline on testing for heritable thrombophilia. Br J Haematol 149: 209-20.

20. National Institute for Health and Clinical Excellence (NICE) (2012) Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing, CG 144.

21. Dentali F, Crowther M, Ageno W (2006) Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis. Blood 107: 2766-73.

22. Zhu T, Martinez I, Emmerich J (2009) Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 29: 298-310.

23. Moodley O, Goubran H (2015) Should lifelong anticoagulation for unprovoked venous thromboembolism be revisited? Thromb J 13: 33.

24. Prandoni P, Barbar S, Milan M, Vedovetto V, Pesavento R (2014) The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities. Eur J Intern Med 25: 25-30.

25. Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, et al. (2014) Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA 312: 1122-35.

26. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, et al. (2012) Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141: e419S-94S.

27. Middeldorp S, van Hylckama Vlieg A (2008) Does thrombophilia testing help in the clinical management of patients? Br J Haematol 143: 321-35.

28. Middeldorp S (2011) Is thrombophilia testing useful? Hematology Am Soc Hematol Educ Program DOI: 10.1182/asheducation-2011.1.150.

Submit your next manuscript to Annex Publishers and benefit from:

- Easy online submission process
- Rapid peer review process
- Online article availability soon after acceptance for Publication
- Open access: articles available free online
- More accessibility of the articles to the readers/researchers within the field
- > Better discount on subsequent article submission

Submit your manuscript at

http://www.annexpublishers.com/paper-submission.php